Resminostat (hydrochloride) – 50 mg

Brand:
Cayman
CAS:
1187075-34-8
Storage:
-20
UN-No:
Non-Hazardous - /

Resminostat is an orally bioavailable inhibitor of histone deacetylase 1 (HDAC1), HDAC3, and HDAC6 (IC50s = 43-72 nM), resulting in hyperacetylation of histone H4 in multiple myeloma cells.{29101} It abrogates cell growth and strongly induces apoptosis in multiple myeloma cells (IC50s = 2.5-3 µM).{29101} Resminostat displays synergistic effects when combined with melphalan and the proteasome inhibitors bortezomib and S-2209.{29101} It dose-dependently inhibits HDAC activity in vivo.{29100}  

 

Available on backorder

SKU: - Category:

Description

An orally bioavailable inhibitor of HDAC1, HDAC3, and HDAC6 (IC50s = 43-72 nM), resulting in hyperacetylation of histone H4 in multiple myeloma cells; abrogates cell growth and strongly induces apoptosis in multiple myeloma cells (IC50s = 2.5-3 µM); dose-dependently inhibits HDAC activity in vivo


Formal name: 3-[1-[[4-[(dimethylamino)methyl]phenyl]sulfonyl]-1H-pyrrol-3-yl]-N-hydroxy-2-propenamide, monohydrochloride

Synonyms:  4SC-201|RAS2410

Molecular weight: 385.9

CAS: 1187075-34-8

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Deacetylases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Epigenetics, Transcription, & Translation|Erasers|Histone Deacetylation